Autoimmune Hepatitis
62
16
19
20
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.1%
5 terminated out of 62 trials
80.0%
-6.5% vs benchmark
11%
7 trials in Phase 3/4
25%
5 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (62)
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
Discrimination of DILI and AIH by Artificial Intelligence
Host-Diet-Gut Interaction Post Vegan Diet in Pediatric Autoimmune Hepatitis.
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
Belimumab in Autoimmune Hepatitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
Machine Learning for Prediction of Therapy Response in Autoimmune Hepatitis
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Liver Cirrhosis Network Cohort Study
Repeatability and Reproducibility of Multiparametric MRI
A Study of SIPLIZUMAB in AILD and LT Patients
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
TruGraf Liver Gene Expression Serial Test
Swiss Autoimmune Hepatitis Cohort Study
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.